However, only 7% of individual plans offered inhome support services and 10% offered general supports for living (e.g., subsidies for rent, assisted living communities, or utilities) as a benefit in 2025
Colvin OM, Friedman HS, Gamcsik MP, Fenselau C, Hilton J
But this does not come from Novo
For those with hypermobility and EDS specifically, Id flag the following as the minimum due diligence before starting these medications: A thorough GI history and ideally gastric emptying assessment if theres any existing dysmotility Baseline muscle mass measurement (DEXA or similar) given the sarcopenia risk A clear plan for high-protein diet and resistance-based exercise to mitigate muscle loss Baseline bone density if theres any existing concern Consideration of the nutritional picture specific to hypermobility, since these drugs can affect appetite and nutrient absorption A conversation specifically about MCAS if thats a feature of your presentation The medication options for hypermobility and EDS are limited and often unsatisfying, and its entirely understandable why people are looking at something new with genuine curiosity
It assists in maintaining carbohydrate stability already in a normal range, helping to optimize fat metabolism and cellular energy production Appetite Suppressant & Craving Control: Stop food noise in its tracks
The many pathways identified include: Dopaminergic signaling Glutamatergic signaling Leptin-mediated pathways PI3K-AKT signaling Histamine signaling Insulin secretion and lipid metabolism These mechanisms influence appetite regulation, reward processing, energy balance, glucose homeostasis, and metabolic control
.png)
